We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

56 hedge funds and large institutions have $340M invested in ProQR Therapeutics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

3.67% more ownership

Funds ownership: 61.3% → 64.97% (+3.7%)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

2% less funds holding

Funds holding: 57 → 56 (-1)

7% less capital invested

Capital invested by funds: $364M → $340M (-$24.8M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $27K

Holders
56
Holders Change
-1
Holders Change %
-1.75%
% of All Funds
1.21%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.06%
New
10
Increased
17
Reduced
15
Closed
11
Calls
–
Puts
$27K
Net Calls
-$27K
Net Calls Change
-$28K

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$48.9M
2
O
OrbiMed
New York
+$8.13M
3
ACM
Aquilo Capital Management
California
+$7.27M
4
NAMA
Nikko Asset Management Americas
New York
+$4.32M
5
Goldman Sachs
Goldman Sachs
New York
+$1.86M

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$45M
2
Morgan Stanley
Morgan Stanley
New York
-$3.52M
3
SFM
Sphera Funds Management
Israel
-$2.24M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.84M
5
Jennison Associates
Jennison Associates
New York
-$1.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$51.8M – – –
RI
2
RTW Investments
New York
$51.6M +$48.9M +3,274,809 +731%
Goldman Sachs
3
Goldman Sachs
New York
$49M +$1.86M +124,466 +4%
Jennison Associates
4
Jennison Associates
New York
$40.1M -$1.59M -106,712 -4%
O
5
OrbiMed
New York
$27.5M +$8.13M +544,300 +38%
AG
6
Artal Group
Luxembourg
$19.4M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$13.3M -$1.84M -123,080 -11%
BlackRock
8
BlackRock
New York
$10.9M +$1.29M +86,149 +12%
PA
9
Perceptive Advisors
New York
$10M – – –
HSBC Holdings
10
HSBC Holdings
United Kingdom
$6.93M – – –
ClearBridge Investments
11
ClearBridge Investments
New York
$6.87M +$43.9K +2,939 +0.6%
ACM
12
Aquilo Capital Management
California
$6.75M +$7.27M +486,698 New
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$6.43M -$254K -17,000 -4%
NAMA
14
Nikko Asset Management Americas
New York
$4.02M +$4.32M +289,511 New
DCM
15
DAFNA Capital Management
California
$3.63M -$164K -10,953 -4%
Federated Hermes
16
Federated Hermes
Pennsylvania
$3.63M – – –
Caisse de Depot et Placement du Quebec (CDPQ)
17
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$3.47M – – –
AGA
18
Altrinsic Global Advisors
Connecticut
$2.76M +$264K +17,700 +10%
SFM
19
Sphera Funds Management
Israel
$2.63M -$2.24M -150,000 -44%
Millennium Management
20
Millennium Management
New York
$2.56M +$1.4M +93,968 +104%
OPPM
21
Opus Point Partners Management
New York
$1.92M – – –
State Street
22
State Street
Massachusetts
$1.57M +$1.05M +70,455 +164%
TCIM
23
TIAA CREF Investment Management
New York
$1.56M +$1.43M +95,806 +583%
Citadel Advisors
24
Citadel Advisors
Florida
$1.14M +$454K +30,367 +58%
Morgan Stanley
25
Morgan Stanley
New York
$1.09M -$3.52M -235,538 -75%
1
2 3

PRQR Hedge Fund Activity: Q1 2019 in Review

56 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2019, worth a combined $340M — down 6.8% from $364M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PRQR and 10 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 17 added.

The largest buyer was RTW Investments, adding an estimated $48.9M. The largest seller was UBS Group, exiting entirely with an estimated $45M sold.

  • 56 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2019, down from 57 in Q4 2018.
  • Funds reported $340M of ProQR Therapeutics stock for Q1 2019, down 6.8% quarter-over-quarter.
  • 10 funds opened new ProQR Therapeutics positions in Q1 2019 and 11 closed out, a net change of -1 holder.
  • The largest ProQR Therapeutics buyer in Q1 2019 was RTW Investments, an estimated $48.9M added.
  • The largest ProQR Therapeutics seller in Q1 2019 was UBS Group, an estimated $45M sold.

Based on aggregated 13F filings for Q1 2019.